Highest-materiality recent filing
Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026
Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.
Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies
Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.
Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering
Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).
Vaxcyte raises $600.2M in public offering of 12.65M shares at $50/share
Offering of 11M shares at $50.00 public price; underwriter option for 1.65M shares exercised.
Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025
Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.
Vaxcyte signs 15-year manufacturing deal with Thermo Fisher's Patheon
Agreement covers formulation, fill, finish, testing at Patheon's Greenville, NC facility.
Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start
Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.
Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025
Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.
Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL
VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.
Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025
Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.
Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on
Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.
Vaxcyte raises $1.42B in underwritten public offering of common stock and pre-funded warrants
Sold 10,194,175 shares at $103.00/share and pre-funded warrants to purchase 2,427,184 shares at $102.999/warrant.
Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria
VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.
Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024
Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.
Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete
Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.
Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B
Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.
the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings